Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Towards a personalized treatment approach for SCD

Raffaella Colombatti • 11 Jun 2022
EHA 2022
Non-Malignant Sickle Cell Disease

Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy, discusses personalized treatment in sickle cell disease (SCD), highlighting the importance of better understanding the biology of SCD and of finding novel biomarkers to eventually allow patients to achieve a quality of life (QoL) comparable to that of healthy individuals. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Raffaella Colombatti

1:17
Novel biomarkers and emerging therapies for sickle cell disease
Raffaella Colombatti • 11 Jun 2022
1:21
The use of radiomics and artificial intelligence for sickle cell disease
Raffaella Colombatti • 11 Jun 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals